Funds will empower Adcentrx to progress its pipeline of novel antibody-drug conjugates into clinical development SAN DIEGO and SHANGHAI, April 24, 2023 /PRNewswire/ — Adcentrx Therapeutics (“Adcentrx”), a biotechnology company dedicated to revolutionizing Antibody-Drug Conjugate (ADC)…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.